XML 34 R13.htm IDEA: XBRL DOCUMENT

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2012
Subsequent Events	Note 7 – Subsequent Events On July 31, 2012, the DoD exercised its option to continue to fund an advanced expression system for the bioproduction of PharmAthene’s rBChE nerve agent medical countermeasure program, under a contract initially awarded in 2011. The value of the option was $2.5 million out of a potential total contract value of $5.7 million.